We love big numbers—in most cases!

With an evidence-based approach, EJHP is aware of a good deal of evidence that the larger the study, the more reliable the results.1 For that reason we will often reject small studies, especially if they are not randomised. Recently we have been receiving submissions analysing large adverse event databases such as (and mainly) FAERS (FDA Adverse Event Reporting System).2 FAERS is the US Food and Drug Administration (FDA)’s central database of adverse drug event reports, used to monitor the safety of all approved medicines and therapeutic biologics. It is one of the world’s largest pharmacovigilance datasets and underpins much of … Correspondence to Professor Philip Wiffen; pwiffen{at}oxfordsrs.org.uk